Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
São Paulo Gov. Joao Doria holds a box of the CoronaVac vaccine during a press conference. Photo: Alexandre Schneider via Getty Images
A coronavirus vaccine produced by Chinese company Sinovac is 78% effective, Brazil officials announced Thursday.
Why it matters: Regulators in other countries are closely following the Phase 3 trials in Brazil. If the vaccine is approved for use, it could help fill a gap in access to coronavirus vaccines for many low- and middle-income countries.
Details: Brazil’s Butantan Institute, a medical research institute in São Paulo, conducted the study of the vaccine, named CoronaVac, with 12,476 volunteers.
- The vaccine prevented all participants from developing severe cases of COVID-19, officials said.
- Brazil has the third-highest number of cases in the world after the U.S. and India, data from Johns Hopkins University shows.
- The Butantan Institute said it will request authorization for emergency use of the vaccine in Brazil, per the Wall Street Journal.
- Other countries, including Turkey and Indonesia, are also testing the CoronaVac vaccine.
The big picture: Sinovac has already sold over 300 million doses, primarily to low- and middle-income countries, per New York Times.
- Sinovac says it will be able to produce 600 million doses this year.
Health regulators in China said late last month that they have approved the country's first homegrown COVID-19 vaccine, developed by the state-owned pharmaceutical company Sinopharm, for general use.
- Sinopharm said that preliminary data have shown the vaccine to be 79.3% effective, though experts have said important data is missing.
Go deeper...The challenge of 2021: Vaccinating the world